7 completed, 6 recruiting, 1 terminated, 1 withdrawn. 6 Phase 2, 3 Phase 1, 3 Phase 3, 3 Phase 4, 2 Not applicable.
Follow Atorvastatin 40mg: new trials by email Literature Review of Atorvastatin 40mg trials Research Report on Atorvastatin 40mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Treatment With Atorvastatin for Episodic Migraine. Atorvastatin 40mg, Placebo, Atorvastatin 20mg - Episodic Migraine | Phase 2 | Recruiting | St. Olavs Hospital | 450 | 2024-05-01 | 2026-07-14 |
| Prophylactic Treatment With Atorvastatin for Chronic Migraine (ChronicStatinMig) Atorvastatin 40mg, Placebo - Chronic Migraine | Phase 2 | Recruiting | St. Olavs Hospital | 300 | 2024-05-01 | 2026-07-20 |
| Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke Atorvastatin 40mg, Rosuvastatin 20mg - Ischemic Stroke | Phase 3 | Recruiting | Kafrelsheikh University | 600 | 2024-04-10 | 2026-04-23 |
| Effect of Ezetimibe on Gut Microbiota Atorvastatin 40mg, Atorvastatin 20mg+Ezetimibe 10mg - Atherosclerotic Cardiovascular Disease With Dyslipidemia | Phase 4 | Recruiting | Yonsei University | 110 | 2024-02-28 | 2025-01-20 |
| ATORvastatin in Pulmonary TUBerculosis Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 440 | 2024-01-03 | 2025-09-25 |
| Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients Rosuvastatin 20 mg, Atorvastatin 40mg - ST-segment Elevation Myocardial Infarction | Phase 2 | Completed | Damanhour University | 80 | 2021-11-01 | 2024-08-01 |
| Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion Atorvastatin 40mg, Placebo oral tablet - Tuberculosis, Pulmonary | Phase 2 / Phase 3 | Recruiting | University of Cape Town | 220 | 2020-07-14 | 2024-08-23 |
| Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. Aspirin 75mg, Clopidogrel 75mg, Rivaroxaban 2.5 MG - COVID-19 | Not applicable | Terminated | Imperial College London | 320 | 2020-04-03 | 2023-01-18 |
| MUscle Side-Effects of Atorvastatin in Coronary Patients Atorvastatin 40mg, Placebo Oral Tablet - Statin Adverse Reaction | Phase 4 | Completed | Vestre Viken Hospital Trust | 77 | 2019-03-05 | 2020-01-03 |
| High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study Atorvastatin 40mg, Placebo - Primary Arteriovenous Fistula Failure | Phase 1 / Phase 2 | Withdrawn | Albany Medical College | 2018-11-01 | 2020-01-18 | |
| A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia Fimasartan 120mg, Atorvastatin 40mg, Placebo for Fimasartan 120mg - Essential Hypertension, Dyslipidemia | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 133 | 2018-01-15 | 2019-11-05 |
| CKD-337(2) Drug-drug Interaction Study Lipitor Tab. 40mg, Trilipix 135mg - Healthy | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2015-03-17 | 2017-08-08 |
| COmparison and Modification in Neointimal Pattern Assessed by Optical Coherence Tomography With High Versus Moderate Efficacy Statin Treatment After Drug Eluting Stent Implantation: COMPASS Trial Atorvastatin 40mg, pravastatin 20 mg - Coronary Artery Disease | Not applicable | Completed | Yonsei University | 30 | 2014-06-01 | 2016-07-27 |
| Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin. Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, atorvastatin 40mg - Essential Hypertension, Hyperlipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2013-04-01 | 2013-08-01 |
| Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime® Versus Cypher SelectTM Stents; SEVEN-Xience Study Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL), Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA), Pravastatin 20mg - Multi-vessel Diseases, Angina | Phase 4 | Completed | Yonsei University | 60 | 2011-08-01 | 2016-07-27 |
Essential Hypertension (2) · Migraine Disorders (2) · Tuberculosis (2) · Tuberculosis, Pulmonary (2) · Angina Pectoris (1) · COVID-19 (1) · Coronary Artery Disease (1) · Coronavirus Infections (1) · Dyslipidemias (1) · Hyperlipidemias (1) · Inflammation (1) · Ischemic Stroke (1) · Pulmonary Disease, Chronic Obstructive (1) · ST Elevation Myocardial Infarction (1) · Stroke (1)
Yonsei University (3) · Chong Kun Dang Pharmaceutical (2) · St. Olavs Hospital (2) · Albany Medical College (1) · Boryung Pharmaceutical Co., Ltd (1) · Damanhour University (1) · Imperial College London (1) · Kafrelsheikh University (1) · Obafemi Awolowo University Teaching Hospital (1) · University of Cape Town (1) · Vestre Viken Hospital Trust (1)
South Korea (6) · Norway (3) · Egypt (2) · Nigeria (1) · South Africa (1) · United Kingdom (1) · United States (1)
Linn H Steffensen, Associate Professor II (2) · Amira B Kassem, PhD (1) · Anne H Aamodt, Senior researcher (1) · Anne H. Aamodt, Senior researcher (1) · Bendik S Winsvold, Post.doc. (1) · Bendik S. Winswold, Post.doc. (1) · Bolanle A Omotoso, MD (1) · Friedrich Thienemann, MD (1) · Kjersti G Vetvik, Ph.d. (1) · Kjersti G. Vetvik, Ph.d. (1) · Loay Salman, MD,MBA (1) · Min Gul Kim (1)
PMID 16731270, PMID 26359512, PMID 31867054, PMID 34515113, PMID 37186070, PMID 39264503